Gabelli analyst Kevin Kedra upgraded Tetraphase Pharmaceuticals (NASDAQ: TTPH) from Hold to Buy with a price target of $5.00.The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE